Numerous researches have showed that the activation of NLRP3 inflammasome and the release of downstream IL-1β and IL-18 can promote the process of liver inflammation, triglyceride deposition, and insulin resistance during the NAFLD/NASH [6–11, 17]. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatohepatitis.